FORM D

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM D

AUG 0 3, 200

OMB APPROVAL

SEC USE ONLY

OMB Number: 3235-0076 Expires: March 30, 2008 Estimated average burden

hours per form.....1

NOTICE OF SALE OF SECURITIES

PURSUANT TO REGULATION D,

SECTION 4(6), AND/OR

UNIFORM LIMITED OFFERING EXEMPTION

Name of Offering (check if this is an ar	mendment and name has chang	ed, a	nd indicate change.)				
Warrant to Purchase Common Stock, Common Stock issuable upon exercise of warrant							
Filing Under (Check box(es) that apply):	☐ Rule 504		☐ Rule 505	■ Rule 506		☐ Section 4(6)	ULOE
Type of Filing:		×	New Filing			Amendment	
A. BASIC IDENTIFICATION DATA							
1. Enter the information requested abou	t the issuer						,
Name of Issuer (check if this is an ame	ndment and name has changed	, and	indicate change.)				
Kosan Biosciences Incorporated							
Address of Executive Offices	(Number and St	reet,	City, State, Zip Code)	Telephone Nun	nber (1	ncluding Area Cod	e)
3832 Bay Center Place, Hayward, California 94545 (510) 732-8400							
Address of Principal Business Operations (Number and Street, City, State, Zip Code) Telephone Number (Including Area Code)							
(if different from Executive Offices)					PROCESSED		
Priof Description of Business							
Brief Description of Business Drug discovery company advancing two new classes of anticancer agents through clinical development.							
Type of Business Organization				N		AA 11 7 50112	
☑ corporation	☐ limited partnership, alread	y for	med	+	,]	HOMEO Meci	fy):
business trust	☐ limited partnership, to be t	-			٦	inancial	•
	,	Ī	Month Y	'ear			
Actual or Estimated Date of Incorporation	or Organization:	C	01 19	995	_		
Luisdistian af Lagamantian an Occasioni	✓ Actual						
Jurisdiction of Incorporation or Organization: (Enter two-letter U.S. Postal Service abbreviation for State: CN for Canada: FN for other foreign jurisdiction) DE						DE	

GENERAL INSTRUCTIONS

Federal

Who Must File: All issuers making an offering of securities in reliance on an exemption under Regulation D or Section 4(6), 17 CFR 230.501 et seq. or 15 U.S.C. 77d(6).

When to File: A notice must be filed no later than 15 days after the first sale of securities in the offering. A notice is deemed filed with the U.S. Securities and Exchange Commission (SEC) on the earlier of the date it is received by the SEC at the address given below or, if received at that address after the date on which it is due, on the date it was mailed by United States registered or certified mail to that address.

Where to File: U.S. Securities and Exchange Commission, 450 Fifth Street, N.W., Washington, D.C. 20549.

Copies Required: Five (5) copies of this notice must be filed with the SEC, one of which must be manually signed. Any copies not manually signed must be photocopies of the manually signed copy or bear typed or printed signatures.

Information Required: A new filing must contain all information requested. Amendments need only report the name of the issuer and offering, any changes thereto, the information requested in Part C, and any material changes from the information previously supplied in Parts A and B. Part E and the Appendix need not be filed with the SEC.

Filing Fee: There is no federal filing fee.

State:

This notice shall be used to indicate reliance on the Uniform Limited Offering Exemption (ULOE) for sales of securities in those states that have adopted ULOE and that have adopted this form. Issuers relying on ULOE must file a separate notice with the Securities Administrator in each state where sales are to be, or have been made. If a state requires the payment of a fee as a precondition to the claim for the exemption, a fee in the proper amount shall accompany this form. This notice shall be filed in the appropriate states in accordance with state law. The Appendix to the notice constitutes a part of this notice and must be completed.

ATTENTION

Failure to file notice in the appropriate states will not result in a loss of the federal exemption. Conversely, failure to file the appropriate federal notice will not result in a loss of an available state exemption unless such exemption is predicated on the filing of a federal notice.

A. BASIC IDENTIFICATION DATA

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1972 (2-97) 1 of 7)

- 2. Enter the information requested for the following:
 - Each promoter of the issuer, if the issuer has been organized within the past five years;
 - Each beneficial owner having the power to vote or dispose, or direct the vote or disposition of, 10% or more of a class of equity securities of the issuer;
 - Each executive officer and director of corporate issuers and of corporate general and managing partners of partnership issuers; and
 - Each general and managing partner of partnership issuers.

Check Box(es) that Apply:	Promoter	■ Beneficial Owner	☐ Executive Officer	Director	General and/or Managing Partner				
Full Name (Last name first, if individual) Daniel V. Santi, M.D., Ph.D.									
Business or Residence Address (Number and Street, City, State, Zip Code) c/o Kosan Biosciences Incorporated, 3832 Bay Center Place, Hayward, California 94545									
Check Box(es) that Apply:	Promoter	Beneficial Owner	Executive Officer	☐ Director	General and/or Managing Partner				
Full Name (Last	Apply: Full Name (Last name first, if individual) Samuel D. Isaly; OrbiMed Advisors LLC; OrbiMed Capital LLC								
Business or Res	idence Address (Number and S	Street, City, State, Zip Code)	-						
767 Third Aver	nue, 30th Floor, New York, N		П:						
that Apply:	Promoter	Beneficial Owner	Executive Officer	Director	☐ General and/or Managing Partner				
	name first, if individual)								
Federated Inve	stors, Inc. idence Address (Number and S	Itreet City State Zin Code)	<u></u>						
	stors Tower, Pittsburgh, PA								
Check Boxes that Apply:	☐ Promoter	Beneficial Owner	☐ Executive Officer	Director	General and/or Managing Partner				
	name first, if individual) nagement Company, LLP								
Business or Res	idence Address (Number and S Boston, MA 02109	Street, City, State, Zip Code)							
Check Boxes that Apply:	☐ Promoter	■ Beneficial Owner	☐ Executive Officer	☐ Director	General and/or Managing Partner				
Full Name (Last	name first, if individual) Associates, Inc.								
	idence Address (Number and S reet, Baltimore, MD 21202	Street, City, State, Zip Code)							
Check Boxes that Apply:	☐ Promoter	☐ Beneficial Owner	Executive Officer	☐ Director	General and/or Managing Partner				
	name first, if individual) son, Jr., M.D., Ph.D.								
Business or Res	idence Address (Number and S	Street, City, State, Zip Code) ay Center Place, Hayward, C	California 94545						
Check Boxes that Apply:	Promoter	Beneficial Owner	Executive Officer	Director	General and/or Managing Partner				
	name first, if individual)								
Margaret A. Horn, J.D. Business or Residence Address (Number and Street, City, State, Zip Code) c/o Kosan Biosciences Incorporated, 3832 Bay Center Place, Hayward, California 94545									
Check Boxes that Apply:	Promoter	☐ Beneficial Owner	Executive Officer	Director	General and/or Managing Partner				
Full Name (Last name first, if individual) Peter J. Licari, Ph.D.									
Business or Residence Address (Number and Street, City, State, Zip Code)									
c/o Kosan Bios	ciences Incorporated, 3832 B	ay Center Place, Hayward, C	California 94545						

A. BASIC IDENTIFICATION DATA

- 2. Enter the information requested for the following:
- Each promoter of the issuer, if the issuer has been organized within the past five years;
- Each beneficial owner having the power to vote or dispose, or direct the vote or disposition of, 10% or more of a class of equity securities of the issuer;
- Each executive officer and director of corporate issuers and of corporate general and managing partners of partnership issuers; and
- Each general and managing partner of partnership issuers.

Check Boxes that Apply:	☐ Promoter	☐ Beneficial Owner	⊠ Executive Officer	☐ Director	☐ General and/or Managing Partner				
Full Name (Last name first, if individual) Pieter B.M.W.M. Timmermans, Ph.D.									
Business or Residence Address (Number and Street, City, State, Zip Code) c/o Kosan Biosciences Incorporated, 3832 Bay Center Place, Hayward, California 94545									
Check Boxes that Apply:	Promoter	☐ Beneficial Owner	Executive Officer	☐ Director	General and/or Managing Partner				
Full Name (Last name first, if individual)									
David L. Johnson Business or Residence Address (Number and Street, City, State, Zip Code)									
		Bay Center Place, Hayward, C							
Check Boxes that Apply:	Promoter	☐ Beneficial Owner	Executive Officer	▼ Director	General and/or Managing Partner				
Full Name (Las Kevan Clemen	name first, if individual) s, Ph.D.								
	idence Address (Number and	Street, City, State, Zip Code) Bay Center Place, Hayward, C	California 94545						
Check Boxes	Promoter	Beneficial Owner	Executive Officer	☑ Director	☐ General and/or				
that Apply:					Managing Partner				
Jean Deleage,									
	idence Address (Number and	Street, City, State, Zip Code) Bay Center Place, Hayward, (California 04545						
Check Boxes	Promoter	Beneficial Owner	Executive Officer	☑ Director	General and/or				
that Apply:					Managing Partner				
Full Name (Las Charles J. Hon	t name first, if individual) ncy, M.D.								
Business or Res	idence Address (Number and								
c/o Kosan Bios Check Boxes		Bay Center Place, Hayward, C		V					
that Apply:	Promoter	☐ Beneficial Owner	☐ Executive Officer	☑ Director	General and/or Managing Partner				
Full Name (Las Chaitan S. Kho	name first, if individual) osla, Ph.D.								
	idence Address (Number and ciences Incorporated, 3832 I	Street, City, State, Zip Code) Bay Center Place, Hayward, C	California 94545						
Check Boxes	Promoter	☐ Beneficial Owner	☐ Executive Officer	☑ Director	☐ General and/or				
that Apply:	name first, if individual)				Managing Partner				
Bruce A. Chab	·								
	idence Address (Number and								
Check Boxes	Promoter	Bay Center Place, Hayward, C Beneficial Owner	Executive Officer	☑ Director	☐ General and/or				
that Apply:		Denencial Owner	Executive officer		Managing Partner				
Full Name (Las Peter Davis, Pl	name first, if individual)								
	idence Address (Number and								
		Bay Center Place, Hayward, (
Check Boxes that Apply:	☐ Promoter	Beneficial Owner	☐ Executive Officer	☑ Director	General and/or Managing Partner				
Full Name (Last name first, if individual) Christopher T. Walsh, Ph.D.									
Business or Residence Address (Number and Street, City, State, Zip Code)									
c/o Kosan Bios	ciences Incorporated, 3832 I	Bay Center Place, Hayward, (California 94545						

1.	Has the issuer sold, or does the issuer intend to sell, to non-accredited investors in this offering? Answer also in Appendix, Column 2, if filing under ULOE.							Y	/es No	<u>X</u>			
2.	2. What is the minimum investment that will be accepted from any individual?									\$ <u>N/A</u>			
3.	3. Does the offering permit joint ownership of a single unit?								У	'es No	_X_		
4.	4. Enter the information requested for each person who has been or will be paid or given, directly or indirectly, any commission or similar remuneration for solicitation of purchasers in connection with sales of securities in the offering. If a person to be listed is an associated person or agent of a broker or dealer registered with the SEC and/or with a state or states, list the name of the broker or dealer. If more than five (5) persons to be listed are associated persons of such a broker or dealer, you may set forth the information for that broker or dealer only.												
Full	Name (Las	t name first, i	f individual)								 -		
Bus	iness or Res	sidence Addre	ss (Number	and Street, (City, State,	Zip Code)							
Nan	ne of Assoc	ated Broker c	r Dealer										
		Person Listed											
•		ites" or check		ŕ									
[AL	-	[AK]	[AZ]	[AR]	[CA]	[CO]	[CT]	[DE]	[DC]	[FL]	[GA]	[HI]	[ID]
[IL]		[IN]	[IA]	[KS]	[KY]	[LA]	[ME]	[MD]	[MA]	[MI]	[MN]	[MS]	[MO]
[MT	•	[NE]	[NV]	[NH]	[NJ]	[NM]	[NY]	[NC]	[ND]	[OH]	[OK]	[OR]	[PA]
[RI]		[SC] t name first, it	[SD] findividual)	[TN]	[TX]	[UT]	[VT]	[VA]	[VA]	[WV]	[WI]	[WY]	[PR]
1 411	Traine (Eas	i namo mot, n	(marridaar)										
Bus	iness or Res	idence Addre	ss (Number	and Street, (City, State,	Zip Code)							
Nan	ne of Assoc	iated Broker o	r Dealer										
State	es in Which	Person Listed	d Has Solicit	ed or Intend	s to Solicit	Purchasers			·				
(Che	eck "All Sta	ites" or check	individual S	tates)			••••••					,	🗖 All States
[AL]	[AK]	[AZ]	[AR]	[CA]	[CO]	[CT]	[DE]	[DC]	[FL]	[GA]	[HI]	[ID]
[IL]		[IN]	[IA]	[KS]	[KY]	[LA]	[ME]	[MD]	[MA]	[MI]	[MN]	[MS]	[MO]
[MT]	[NE]	[NV]	[NH]	[NJ]	[NM]	[NY]	[NC]	[ND]	[OH]	[OK]	[OR]	[PA]
[RI]		[SC]	[SD]	[TN]	[TX]	[UT]	[VT]	[VA]	[VA]	[WV]	[WI]	[WY]	[PR]
Full	Name (Las	t name first, it	f individual)										
Bus	iness or Res	idence Addre	ss (Number	and Street, (City, State,	Zip Code)							
Name of Associated Broker or Dealer													
State	es in Which	Person Listed	d Has Solicit	ed or Intend	s to Solicit	Purchasers	·						
(Che	eck "All Sta	ites" or check	indiviđual S	tates)	•••••								🗖 All States
[AL]	[AK]	[AZ]	[AR]	[CA]	[CO]	[CT]	[DE]	[DC]	[FL]	[GA]	[HI]	[ID]
[IL]		[IN]	[IA]	[KS]	[KY]	[LA]	[ME]	[MD]	[MA]	[MI]	[MN]	[MS]	[MO]
[MT]	[NE]	[NV]	[NH]	[NJ]	[NM]	[NY]	[NC]	[ND]	[OH]	[OK]	[OF.]	[PA]
[RI]		[SC]	[SD]	[TN]	[XX]	[UT]	[VT]	[VA]	[VA]	[WV]	[WI]	[WY]	[PR]

B. INFORMATION ABOUT OFFERING

C. OFFERING PRICE, NUMBER OF INVESTORS, EXPENSES AND USE OF PROCEEDS Enter the aggregate offering price of securities included in this offering and the total amount already sold. Enter "0" if answer is "none" or "zero." If the transaction is an exchange offering, check this box \square and indicate in the columns below the amounts of the securities offered for exchange and already exchanged.

	Type of Security	Aggregate Offering Price	Amount Already Sold
	Debt	\$	\$
	Equity	\$	\$
	Common Preferred		
	Convertible Securities (including warrants)	\$1,407,900.00	\$0
	Partnership Interests	\$	\$
	Other (Specify)	\$	\$
	Total	\$ 1,407,900.00	\$0
	Answer also in Appendix, Column 3, if filing under ULOE.	·	
2.	Enter the number of accredited and non-accredited investors who have purchased securities in this offering and the aggregate dollar amounts of their purchases. For offerings under Rule 504, indicate the number of persons who have purchased securities and the aggregate dollar amount of their purchases on the total lines. Enter "0" if answer is "none" or "zero."		
	·	Number	Aggregate
		Investors	Dollar Amount
			of Purchases
	Accredited Investors	1	\$1,407,900.00
	Non-accredited Investors	0	\$0.00
	Total (for filings under Rule 504 only)		\$
	Answer also in Appendix, Column 4, if filing under ULOE.		
3.	If this filing is for an offering under Rule 504 or 505, enter the information requested for all securities sold by the issuer, to date, in offerings of the types indicated, in the twelve (12) months prior to the first sale of securities in this offering. Classify securities by type listed in Part C - Question 1.		
		Type of	Dollar Amount
		Security	Sold
	Type of Offering		
	Rule 505		\$
	Regulation A		\$
	Rule 504		\$
	Total		\$
4.	a. Furnish a statement of all expenses in connection with the issuance and distribution of the securities in this offering. Exclude amounts relating solely to organization expenses of the issuer. The information may be given as subject to future contingencies. If the amount of an expenditure is not known, furnish an estimate and check the box to the left of the estimate.		
	Transfer Agent's Fees		\$
	Printing and Engraving Costs		\$
	Legal Fees	X	\$
	Accounting Fees		\$
	Engineering Fees		\$
	Sales Commissions (specify finders' fees separately)		\$
	Other Expenses (Identify)		\$
	Total	×	\$7,500.00

C. OFFERING PRICE, NUMBER OF I	INVESTORS, EXPENSES AND USE OF PROCEEDS	
 Enter the difference between the aggregate offering price given in response to Part C – Question 4.a. This difference is the "adjuste" 	esponse to Part C - Question 1 and total expenses furnished d gross proceeds to the issuer"	\$ <u>1,400,400.00</u>
5. Indicate below the amount of the adjusted gross proceeds to the issuer use If the amount for any purpose is not known, furnish an estimate and payments listed must equal the adjusted gross proceeds to the issuer set in the indicate of th	check the box to the left of the estimate. The total of the	Payment To Others
Salaries and fees	•	
Purchase of real estate		□ s
Purchase, rental or leasing and installation of machinery and equipment		
Construction or leasing of plant buildings and facilities		□ s
Acquisition of other businesses (including the value of securities involved ir in exchange for the assets or securities of another issuer pursuant to a merger)		
Repayment of indebtedness	Δ φ	□ \$
Working capital	Ψ	x \$ 1,400,400.00
Other (specify):	∟ S	□ s
		□ s
Column Totals		x \$1,400,400.00
Total Payments Listed (column totals added)	\$	1,400,400.00
	DERAL SIGNATURE	
The issuer had duly caused this notice to be signed by the undersigned duly an undertaking by the issuer to furnish to the U.S. Securities and Exchange on non-accredited investor pursuant to paragraph (b)(2) of Rule 502.	authorized person. If this notice is filed under Rule 505, the	following signature constitutes n furnished by the issuer to any
The issuer had duly caused this notice to be signed by the undersigned duly an undertaking by the issuer to furnish to the U.S. Securities and Exchange 0	authorized person. If this notice is filed under Rule 505, the Commission, upon written request of its staff, the information	following signature constitutes n furnished by the issuer to any
The issuer had duly caused this notice to be signed by the undersigned duly an undertaking by the issuer to furnish to the U.S. Securities and Exchange (non-accredited investor pursuant to paragraph (b)(2) of Rule 502. Issuer (Print or Type) Kosan Biosciences Incorporated	authorized person. If this notice is filed under Rule 505, the Commission, upon written request of its staff, the information Signature Muyaut A. Horn	n furnished by the issuer to any
The issuer had duly caused this notice to be signed by the undersigned duly an undertaking by the issuer to furnish to the U.S. Securities and Exchange (non-accredited investor pursuant to paragraph (b)(2) of Rule 502. Issuer (Print or Type)	authorized person. If this notice is filed under Rule 505, the Commission, upon written request of its staff, the information	n furnished by the issuer to any Date
The issuer had duly caused this notice to be signed by the undersigned duly an undertaking by the issuer to furnish to the U.S. Securities and Exchange (non-accredited investor pursuant to paragraph (b)(2) of Rule 502. Issuer (Print or Type) Kosan Biosciences Incorporated	authorized person. If this notice is filed under Rule 505, the Commission, upon written request of its staff, the information Signature Muyaut A. Horn	Date July 27, 2006
The issuer had duly caused this notice to be signed by the undersigned duly an undertaking by the issuer to furnish to the U.S. Securities and Exchange (non-accredited investor pursuant to paragraph (b)(2) of Rule 502. Issuer (Print or Type) Kosan Biosciences Incorporated Name of Signer (Print or Type)	Signature Title of Signer (Print or Type) Senior Vice President, Legal and Corporate Developm	Date July 27, 2006
The issuer had duly caused this notice to be signed by the undersigned duly an undertaking by the issuer to furnish to the U.S. Securities and Exchange (non-accredited investor pursuant to paragraph (b)(2) of Rule 502. Issuer (Print or Type) Kosan Biosciences Incorporated Name of Signer (Print or Type)	Signature Title of Signer (Print or Type) Senior Vice President, Legal and Corporate Developm	Date July 27, 2006
The issuer had duly caused this notice to be signed by the undersigned duly an undertaking by the issuer to furnish to the U.S. Securities and Exchange (non-accredited investor pursuant to paragraph (b)(2) of Rule 502. Issuer (Print or Type) Kosan Biosciences Incorporated Name of Signer (Print or Type)	Signature Title of Signer (Print or Type) Senior Vice President, Legal and Corporate Developm	Date July 27, 2006
The issuer had duly caused this notice to be signed by the undersigned duly an undertaking by the issuer to furnish to the U.S. Securities and Exchange (non-accredited investor pursuant to paragraph (b)(2) of Rule 502. Issuer (Print or Type) Kosan Biosciences Incorporated Name of Signer (Print or Type)	Signature Title of Signer (Print or Type) Senior Vice President, Legal and Corporate Developm	Date July 27, 2006
The issuer had duly caused this notice to be signed by the undersigned duly an undertaking by the issuer to furnish to the U.S. Securities and Exchange (non-accredited investor pursuant to paragraph (b)(2) of Rule 502. Issuer (Print or Type) Kosan Biosciences Incorporated Name of Signer (Print or Type)	Signature Title of Signer (Print or Type) Senior Vice President, Legal and Corporate Developm	Date July 27, 2006
The issuer had duly caused this notice to be signed by the undersigned duly an undertaking by the issuer to furnish to the U.S. Securities and Exchange (non-accredited investor pursuant to paragraph (b)(2) of Rule 502. Issuer (Print or Type) Kosan Biosciences Incorporated Name of Signer (Print or Type)	Signature Title of Signer (Print or Type) Senior Vice President, Legal and Corporate Developm	Date July 27, 2006
The issuer had duly caused this notice to be signed by the undersigned duly an undertaking by the issuer to furnish to the U.S. Securities and Exchange (non-accredited investor pursuant to paragraph (b)(2) of Rule 502. Issuer (Print or Type) Kosan Biosciences Incorporated Name of Signer (Print or Type)	Signature Title of Signer (Print or Type) Senior Vice President, Legal and Corporate Developm	Date July 27, 2006
The issuer had duly caused this notice to be signed by the undersigned duly an undertaking by the issuer to furnish to the U.S. Securities and Exchange (non-accredited investor pursuant to paragraph (b)(2) of Rule 502. Issuer (Print or Type) Kosan Biosciences Incorporated Name of Signer (Print or Type)	Signature Title of Signer (Print or Type) Senior Vice President, Legal and Corporate Developm	Date July 27, 2006
The issuer had duly caused this notice to be signed by the undersigned duly an undertaking by the issuer to furnish to the U.S. Securities and Exchange (non-accredited investor pursuant to paragraph (b)(2) of Rule 502. Issuer (Print or Type) Kosan Biosciences Incorporated Name of Signer (Print or Type)	Signature Title of Signer (Print or Type) Senior Vice President, Legal and Corporate Developm	Date July 27, 2006
The issuer had duly caused this notice to be signed by the undersigned duly an undertaking by the issuer to furnish to the U.S. Securities and Exchange (non-accredited investor pursuant to paragraph (b)(2) of Rule 502. Issuer (Print or Type) Kosan Biosciences Incorporated Name of Signer (Print or Type)	Signature Title of Signer (Print or Type) Senior Vice President, Legal and Corporate Developm	Date July 27, 2006

ATTENTION

Intentional misstatements or omissions of fact constitute federal criminal violations. (See 18 U.S.C. 1001.)

	E. STA	TE SIGNATURE			
1.	Is any party described in 17 CFR 230.262 presently subject to any of the disqualification provisions of such rule?				
	See Appendix, C	Column 5, for state response.			
2.	2. The undersigned issuer hereby undertakes to furnish to the state administrator of any state in which the notice is filed, a notice on Form D (17 CFR 2 such times as required by state law.				
3.	The undersigned issuer hereby undertakes to furnish to any state administr	rators, upon written request, information furnished by the is	ssuer to offerees.		
4.	The undersigned issuer represents that the issuer is familiar with the conditions that must be satisfied to be entitled to the Uniform limited Offering Exemption (ULOE) of the state in which this notice is filed and understands that the issuer claiming the availability of this exemption has the burden of establishing that these conditions have been satisfied.				
	e issuer has read this notification and knows the contents to be true and h son.	as duly caused this notice to be signed on its behalf by the	he undersigned duly authorized		
Issu	uer (Print or Type)	Signature	Date		
Kosan Biosciences Incorporated. Marguet A. H. J			July 27, 2006		
Name (Print or Type) Title (Print or Type)					
Margaret A. Horn Senior Vice President, Legal and Corporate Development, General Counsel and Secretary					

Instruction:

Print the name and title of the signing representative under his signature for the state portion of this form. One copy of every notice on Form D must be manually signed. Any copies not manually signed must be photocopies of the manually signed copy or bear typed or printed signatures.